- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04872465
TBS Over DLPFC in Elderly Refractory Depression
January 13, 2023 updated by: Che-Sheng Chu, Kaohsiung Veterans General Hospital.
Efficacy of Bilateral Dorsolateral Prefrontal Theta-burst Stimulation in Elderly Refractory Depression: a Randomized Sham-controlled Study
The study aim to examine the effect of Thea-burst stimulation over bilateral dorsolateral prefrontal cortex (DLPFC) among patients with LLD on mood condition and relevant biomarkers.
Study Overview
Detailed Description
Thea-burst stimulation (TBS) is a novel form of rTMS, providing greater modulation effect on neural activity.
So far, no study was conducted to use TBS as treatment in LLD.
Therefore, we aim to examine the effect of TBS over bilateral dorsolateral prefrontal cortex (DLPFC) among patients with LLD on mood condition and relevant biomarkers.
The study used a two-arm, parallel, double-blind, randomized, and sham-controlled design.
We plan to enroll sixty patients with LLD, thirty for active intervention and thirty for sham-controlled group.
An Magstim Rapid2 stimulator with eight-figure coil was used for stimulation.
Location of brain area are based on bilateral DLPFC.
3-pulse 50-Hz bursts was given every 200ms (at 5 Hz) and an intensity of 80% active motor threshold was settled.
We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day.
After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).
Each patient received daily stimulation for two weeks with total ten sessions.
The primary outcomes were change of depression severity including response and remission rate.
Secondary outcome were biomarkers related to depression.
Assessments were administered at baseline, immediately after 5 and 10 sessions of stimulation, and 3 months after the completion of stimulation.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Che-Sheng Chu, MD
- Phone Number: 72068 +886-7-3422121
- Email: cschu@vghks.gov.tw
Study Locations
-
-
-
Kaohsiung, Taiwan, 813
- Recruiting
- Department of Psychiatry, Kaohsiung Veterans General Hospital
-
Contact:
- Che-Sheng Chu, MD
- Phone Number: 72068 +886-7-3422121
- Email: cschu@vghks.gov.tw
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged 60 to 85 years
- Major depression disorder
- Under a stable dose of all psychotropic medication during the stimulation period.
Exclusion Criteria
- Having any current psychiatric comorbidity or history of substance dependence.
- Having active suicidal ideation currently.
- Having severe physical illness, recent and/or current unstable medical disorders.
- Having history of cancer or chemotherapy.
- Dementia or MMSE<24.
- Having TMS contraindicated (seizure disorder, history of seizures, metal in the head, pacemakers, history of craniotomy)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Experimental
We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day.
After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).
|
We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day.
After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).
|
Placebo Comparator: Sham Comparator
Participants will receive sham (placebo) TBS treatment the same as experimental group
|
Participants will receive sham (placebo) TBS treatment the same as experimental group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hamilton Depression Rating Scale, HAM-D
Time Frame: Change from baseline after 1, 2 weeks and three months
|
The Ham-D is the most widely used clinician-administered depression assessment scale.
The original version contains 17 items pertaining to symptoms of depression experienced over the past week.
A score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher (indicating at least moderate severity) is usually required for entry into a clinical trial.
|
Change from baseline after 1, 2 weeks and three months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Beck depression inventory, BDI-II
Time Frame: Change from baseline after 1, 2 weeks and three months
|
The BDI-II was a 1996 revision of the BDI.
Participants were asked to rate how they have been feeling for the past two weeks.
BDI-II also contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms.
The standardized cutoffs used as follows: 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; 29-63: severe depression.
|
Change from baseline after 1, 2 weeks and three months
|
Beck anxiety inventory, BAI
Time Frame: Change from baseline after 1, 2 weeks and three months
|
The BAI, created by Aaron T. Beck and other colleagues, is a 21-question multiple-choice self-report inventory that is used for measuring the severity of anxiety in children and adults.
The BAI contains 21 questions, each answer being scored on a scale value of 0 (not at all) to 3 (severely).
Higher total scores indicate more severe anxiety symptoms.
The standardized cutoffs are as follows: 0-7: minimal anxiety; 8-15: mild anxiety; 16-25: moderate anxiety; 26-63: severe anxiety.
|
Change from baseline after 1, 2 weeks and three months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Che-Sheng Chu, MD, Kaohsiung Veterans General Hospital.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 6, 2022
Primary Completion (Anticipated)
July 31, 2024
Study Completion (Anticipated)
July 31, 2024
Study Registration Dates
First Submitted
May 2, 2021
First Submitted That Met QC Criteria
May 3, 2021
First Posted (Actual)
May 4, 2021
Study Record Updates
Last Update Posted (Estimate)
January 16, 2023
Last Update Submitted That Met QC Criteria
January 13, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Kaohsiung VGHKS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depression
-
Stanford UniversityTerminatedMajor Depressive Disorder | Major Depressive Episode | Major Depressive Disorder, Recurrent | Major Depression Mild | Major Depression Moderate | Major Depression SevereUnited States
-
Hawler Medical UniversityCompleted
-
Centre Hospitalier Universitaire de BesanconH. Lundbeck A/SCompletedResistant Major DepressionFrance
-
First Affiliated Hospital of Zhejiang UniversityRecruiting
-
University of PittsburghCompletedPostpartum Major DepressionUnited States
-
Si TianmeiUnknownMajor Depression DisorderChina
-
The Hong Kong Polytechnic UniversityNot yet recruitingHealthy | Major Depression in Remission
-
AstraZenecaCompletedNon-psychotic Unipolar Major DepressionArgentina
-
Ruijin HospitalTerminatedTreatment Resistant Major Depression DisorderChina
-
Zentrum für Integrative PsychiatrieGerman Research FoundationCompletedCognitive Performance in Major DepressionGermany
Clinical Trials on TBS
-
University Hospital, CaenUnknownSocial Cognition in Patients With SchizophreniaFrance
-
University of Texas at AustinRecruitingMild Cognitive ImpairmentUnited States
-
Stanford UniversityCompletedTreatment Resistant DepressionUnited States
-
University of ArizonaNational Institute on Aging (NIA)RecruitingMild Cognitive ImpairmentUnited States
-
Stanford UniversityRecruitingTreatment Resistant DepressionUnited States
-
Stanford UniversityRecruitingTreatment Resistant DepressionUnited States
-
Wake Forest University Health SciencesCompletedBack Pain | Chronic Pain | Neuropathic Pain | Opioid Use | Pain, Chronic | Opiate Dependence | Chemotherapy-induced Peripheral Neuropathy | Chronic Lower Back PainUnited States
-
Stanford UniversityNot yet recruitingTreatment Resistant DepressionUnited States
-
Stanford UniversityRecruiting
-
QualissimaPharmacog's project (IMI)Terminated